All right, welcome back. Good morning. I'm Larry Biegelsen, the med tech analyst at Wells Fargo, and it's my pleasure to host this fireside chat with the management team from Insulet. With us from the company are Ana Chadwick, the CFO, and Eric Benjamin, Executive Vice President, Chief Product and Consumer Experience Officer. The format is fireside chat. If anybody has a question, just raise your hand. We'll come around with a mic. Ana and Eric, thanks so much for being here. Our pleasure. Of course, we have Deb Gordon in the audience, the Head of Investor Relations. So, let's start off with the exciting recent news, the type two approval last week. I think it was about four months ahead of our expectations. For Eric or Ana, you know, just talk about the launch plan, please. Very great place to start. Our business is firing on all cylinders, as we shared on our Q2 call just a couple of weeks ago. We raised guidance across the board, top line up to 16%-19%, gross margin now at the high end of our guide at 69%, and 14% operating margin. So we're seeing the core business accelerate. We've got exciting catalysts to come in the second half, and we just added on top of that, the Type 2 indication coming early as of last week. So a really exciting time at Insulet. That launch, we have an incredible opportunity to start right where we have strength today. So as a reminder, the label that we got for Omnipod 5 is for all insulin-requiring people who live with Type 2 diabetes. We think of that as two markets. That's about two and a half million people who live with insulin-intensive Type 2 diabetes. They're already on basal-bolus insulin. Their insulin needs look a lot like those who live with Type 1 diabetes. It's also three to four million folks who take basal insulin. We can talk a little bit about why we have some excitement about that market down the road, but where we're going to start is right where we have strength. So this is two and a half million people with insulin, who live with insulin-intensive Type 2 diabetes. That market's under 5% penetrated today. So the first thing that we began doing last week when the clearance came early, was bringing that new indication to our existing call point. We know that there's a lot of surprise, actually, in the healthcare community about how well technology can do to improve the lives of people who live with Type 2 diabetes. We demonstrated extraordinary clinical outcomes in our Type 2 study, the SECURE-T2D trial. One of the many positive surprises from that trial was actually how well people who live with Type 2 diabetes did with technology. So we are going to start where we have strength. We're going to help educate the folks that we call on today that Type 2 diabetes can be treated with Omnipod 5 and deliver great clinical outcomes. Second stage of the launch, we have really strong direct consumer advertising capabilities. We get about half our leads today, are folks who live with Type 2 diabetes. For the last eighteen months, we've had to pivot those folks to our DASH product when they've reached out to us asking for assistance getting on product. We now have an opportunity to engage in the conversation that those patients want, which is to help them get onto Omnipod 5. So we've got a near-term opportunity to just be more effective, the commercial channels we have now. And then in the next few months, we'll also be expanding our sales force. That for us is doing more of what we already know how to do. We cover endos, and some endo-like primary care providers today. When we look at the opportunity, we can make a modest, right-sized expansion of the sales force to make the most of the Type 2 indication in 2025. Again, we look at a massive opportunity of 2.5 million people who live with insulin-intensive Type 2 diabetes. We're going to go after that in stages. But the pieces are in place, commercial, you know, coverage, everything is covered? Yeah. So great clarification. Our... We have coverage. So Omnipod 5 is very well covered for Type 2 diabetes today. Essentially, the coverage that we have for Omnipod 5 directly applies to Type 2. There are a few little opportunities to bring those into parity, but they're at the margins. We're coming out of the gate with coverage for Type 2. And the label, is there any difference? DASH had a Type 2 indication, right? Correct. Is there any difference between the labels for DASH and for Omnipod 5 for type two? The wonderful thing, both DASH and Omnipod 5 are covered for insulin-requiring people with type 2 diabetes. So this is a sale that we got good at when we were before the launch of Omnipod 5, and now we have the opportunity to leverage that strength as we go bring Omnipod 5 to those who live with insulin-requiring type 2 diabetes. I know it's not the primary target, but the basal population. Why would a basal patient want or benefit from a pump? Couple pieces on that one, Larry. So starting with the SECURE-T2D trial, we enrolled about three hundred folks in the SECURE-T2D trial. That was our study of Omnipod 5 and those with insulin-requiring Type 2 diabetes. We enrolled 20%-25% of the subjects in that study who were on basal insulin. One of the things that we felt very strongly about is we wanted this to be an incredibly real-world study. So we took people as they were. We didn't try to teach them new things about diabetes, we just helped them get on to Omnipod 5. The 20%-25% people in the study on basal-only insulin. The reason that that makes sense is when one lives with insulin-requiring Type 2 diabetes, the largest glycemic excursions happen around meals. So what people who live with Type 2 diabetes really need is insulin for meals. We tend to give them long-acting insulin because we're not convinced that we can get them to take insulin at meals, but physiologically, what they need is insulin at meals. What Omnipod 5 does is it just gives them, in a much more physiological way, automated insulin delivery every five minutes to get them the insulin that they need. So if they get on the Omnipod 5, they get glycemic excursions down around meals. At times they don't need insulin, they get less insulin. So they get all the benefits of automation, they get better clinical outcomes, and they feel better. Got it. And, sales force expansion, how many and what are the margin implications? Not ready to guide on the how many. It'll be incremental. So again, it's a model that we know well. So we're going to take the selling model that we do today. We're going to go to the next tranche of natural prescribers, folks who write a lot of CGM, folks who write a lot of rapid-acting insulin, for whom our current commercial model is a good fit. So we'll grow that footprint, and we'll do that in a way that is consistent with our plan to continue expanding margins. But I'm sure Ana would like to weigh in. Yeah, so I'll touch here for 2024, which is where we provided guidance. We were anticipating some increase in our sales force, so that's already baked into the guidance. And part of the reason we were doing that is because we wanted to prepare for the bigger launch with the type two indication. It came in a little earlier, but we were hiring those people, making sure they're trained, because, you know, there's a lead time. So it's just a matter of a few months, but we already had in our guidance, baked in some increase in our sales force. Historically, Ana, you've talked about increasing the operating margin by about a hundred basis points, or at least a hundred basis points a year. I just want to confirm that this expansion doesn't take you off track from that beyond twenty twenty-four. No, actually, I would argue it gives us more confidence because a lot of our margin expansion comes with scale, and this only reiterates our larger scale. And what I mean by that margin expansion is over time. I mean, not every quarter will be perfect in terms of the exact amount, but over time, a hundred basis points should be a floor. Okay. And then I guess maybe the last piece on Type 2. Well, I have a couple more questions, but you talked about it coming a little bit earlier, and I guess how does this impact your new start growth in the ramp in the second half and full year? Maybe just- Yeah. Remind us or tell us now, update us on your latest thinking about U.S. new starts, because you, you know it as well as I, it's a pretty big focus for investors. Yeah, absolutely. So what it does, this Type 2 indication coming earlier, it gives us more confidence to what we have stated, and I just want to recap what we stated before. We are seeing sequential quarter over quarter growth. Second quarter, we saw that. We anticipate that in third and fourth quarter. We also anticipate the second half of 2024 to be higher than the second half of 2023, and going back to your point, receiving this indication months earlier than we anticipated, just gives us more confidence. The other thing I wanted to point out is new customer starts are, we know, hugely important. The financial benefit in terms of revenue goes into our annuity model, and most of that will be felt in our financial profile in 2025, especially as we move into the second half of 2025 and beyond. And more to come as we are paving this new path with Type 2. We'll come back to all of you guys and give you a view of 2025 once we wrap up 2024. That's helpful. One follow-up. Just could you remind us of what your latest thinking is on full year 2024, year-over-year growth in new starts in the U.S.? It was a little unclear at the end of the call. You made some comments. It wasn't clear to me if you were talking about the second half of the year or the full year. So the question is: Do you expect full year 2024 new starts in the U.S. to be higher, A? And then B, what about Q3? I heard you say second half higher. What about Q3? Sure, let me clarify that. We expect second half U.S. new customer starts for the second half of 2024 to be higher than 2023. Let's go back to the calendar year of 2023 full year. That was a massive Omnipod 5 launch year. So at the moment, just to reiterate, for the U.S., we expect the second half of 2024 to be higher than the second half of 2023. To call exactly if third quarter will be higher or not, it's very hard. The way we have it modeled, it happens somewhere in between that third and fourth quarter, so it's a little bit hard to call. Now, with Type 2 indication, maybe we get a little bit more confident, but I think the essence is, let's not split hairs between third and fourth quarter. It's the overall trend and that sequential growth we're seeing second, third and fourth quarter. Okay, that's helpful. I mean, Eric, you and I have talked about this before, the way we think about it, one way to think about it, obviously the penetration you talked about in Type 2 being sub 5%. But another way we look at it is, you know, before Omnipod 5, you know, when you had DASH, it was 35%-40% of new starts were coming from Type 2. Today, it's 25%. So we can, like, look at all else being equal, you know, for Type 1, what if new starts, you know, it goes to 25%, goes to somewhere between 35%-40%. What are the implications? I guess, do you expect maybe starting— Do you expect it to go back to 35%-40% of new starts to come from type two, like you saw with Dash? Is that one way of thinking about it? ... I don't think we've guided to a mix on Type 1, Type 2, Larry, but maybe a couple of ways that we do think about what this looks like now with the Type 2 indication. First, we think of the Type 2 indication as incremental, so we do therefore expect that the fraction of our business will move towards Type 2. You know, the other thing as I was talking through the components of the launch, we have a lot of confidence that we can start with the commercial model that we have to drive leverage out of that. So that also means we have an opportunity to get impact in a reasonable length of time, which is terrific. The thing that we're just very conscious of is there's work to do in the market to help the market fully embrace technology for those who live with insulin requiring Type 2 diabetes. We're excited to go do that work. We've got best-in-class clinical data to make it happen, and that's what our team is out there doing, is bringing the benefits of our Omnipod 5 to those who can prescribe it, to those with insulin requiring Type 2 diabetes, so we're excited to see incremental growth. We're going to start with the commercial model that we have and drive from there. And I'll push my luck a little bit with one more for Ana. You know, growth in new starts in the U.S. in the second half, I heard that. People care about 2025, you know that. Does this—it seems like, you know, growing in the second half, new starts and with the Type 2 indication, just ramping, it bodes well for growth in new starts in 2025, my view. Would you agree? I think it's a very accurate view. Okay. Okay, fair enough. Okay, let's. Let me ask a couple of questions on competition. Just switching gears. Anything else, Eric, on Type 2 you want to add? You think we covered Type 2? I think we covered it. Maybe just to close, it's a huge underpenetrated market, how we think about it. We're going to drive short-term impact because we've got commercial leverage, but we've got two and a half million people with insulin-intensive Type 2 diabetes that we're going to go bring technology to. We've also got three to four million folks with who take basal insulin today, and we've shown they will get benefits from Omnipod 5. That's not a today, but that's a down the road. And as we do the work to educate the market and drive growth, we're really excited about the opportunity for both of those markets. All right, so shifting gears, competition. There's more competition. Tandem's out there with Mobi, Medtronic. It's coming with 780G and Simplera. There's a private company out in the market that's, you know, had gotten some traction. What's your view of the increased competition in the U.S.? We see two things, Larry. The first is our business is really strong, and we see we're confident in the strength of Omnipod 5, our leadership position, and we're really excited about the catalysts that are coming in the second half of the year. I think the other thing we see is that the space is getting a little stickier across the board. There are fewer customers switching from one brand to another, and that's okay, because that isn't our focus. Our focus is bringing the benefits of technology to those who are currently not yet benefiting from technology. Those are the big two. You know, when we think about how our business is performing, in the eighth quarter of the Omnipod 5 launch, which was the second quarter of 2024, that was eight quarters into the Omnipod 5 launch, we delivered sequential growth after three competitors had entered the market, and that was right before we launched our G7 integration, which is a tailwind for us in the second half, before the Type 2 indication came early, and before our Libre 2+ indication, which is coming to the US before the end of the year, also before our iOS limited market release and full market release, which are coming before the end of the year. So when we look at the setup, we see huge strength that we're proud of the team for delivering in the second quarter, and a whole series of catalysts that are going to help us continue to maintain the leadership position we enjoy in the market. iOS. I, like, got an email alert that it's, like, now available. So you said, like, the full... Is it, is it fully launched now, iOS with Omnipod 5? We just sent a notice to all of our customers. It'll be in the App Store in the middle of October. Got it. And iOS and G7, when will that be available? Omnipod 5 with G7 will come in 2025. So- Omnipod 5 G7 iOS, you mean? Thank you. Omnipod 5, iOS G7 will come in 2025. Got it. Not easy to keep track. Indeed. While we're on competition, what's your take on the Abbott Medtronic integration? We're really happy with the fact that we get to partner with two great sensor partners to bring the benefits of automated insulin delivery to people who live with diabetes. It helps to have great partners in the market who give us the option to bring sensor of choice to customers. If we think about who in the market has not yet adopted technology, so if we just put ourselves in the minds of a person who's walking into a healthcare provider's office, who lives with diabetes, and they're not yet using technology, a couple things. One, they probably know about legacy technology because, too, legacy tubed pumps have been on the market for almost 40 years, and they've not chosen those. And the second thing, they're probably on CGM. Those are sort of the two market facts that we think about when we think about who our future customers are. A lot of the choices that we make as we're going to market to drive growth is about how we make it the shortest distance for those customers to enjoy the benefits of Omnipod 5? So we want to make that as easy for the customer and for the healthcare provider who cares for them. By offering sensor of choice, we make that easier because if somebody's already on a great sensor, we can bring Omnipod 5 to them without them having to change sensor. Not a huge obstacle, but it helps bring that burden down, makes it easier to get onto Omnipod 5. That's why G7 is a nice tailwind for us in the second half of the year. It's also why sensor of choice is a benefit going forward. We're really proud of having two great sensor partners with whom we can offer choice. When we look at the move that one of our partners made with one of our competitors, we don't see it affecting that choice, and we don't see it affecting the fact that we benefit from differentiated technology that gives us leadership in the market. Okay. I would be remiss if I didn't ask about, you know, the latest competitor that was just cleared in Beta patch pump. It's an open system, so it's not integrated with CGM, so that's a big difference. But they're developing a closed loop system, what they've said publicly. What's your--what-- Just I'd love to get your reaction to it. And, you know, they're highlighting that there's 300 units versus your 200 units. What... A couple of questions, but I'm just curious to get your high-level thoughts. Yeah, Larry, maybe two perspectives, one on sort of general small-scale competitors and one on the size of reservoir. You know, I guess a couple things. Insulet got its first clearance for an open loop patch pump in the mid-2000s, so about twenty years ago. So when we just think about where a would-be patch pump competitor is in the life cycle to get to the place that we're going, which is phone control at scale, cost-effective, high quality, high reliability, integrated with multiple sensors and cloud-connected AID system, we just don't see anybody who's close. And recent news is very much in that bucket of not close. When we think about reservoir, that's a really important question, given the way we started this conversation about type two. One of the really interesting nuggets from our Type 2 pivotal study was actually that the amount of insulin that people need when they get insulin physiologically goes down significantly. So the headlines on that are, in the entire study, insulin use went down about 30%. So we didn't have any restrictions on total daily insulin going into the study. We had folks in the, I think, low double digits was the low end. I'd have to double-check that one, and up above 300 units a day at the high end, 'cause we didn't restrict it. We took all comers, and that whole population 30% reduction. Those who were on more than 100 units a day of study saw more than 50% reduction in the insulin that they needed when they got insulin with Omnipod 5. So what that says to us is the data shows Omnipod 5 is going to provide a great experience with adequate capacity for a lot of the people with insulin-requiring diabetes because they're getting insulin more physiologically and therefore require less insulin. Let me play devil's advocate. There are some patients that are going to need more than 200 over three days, and I've looked at your data, SECURE-T2D data, pretty closely. Yeah. And why is three hundred not better than two hundred? Why is more not better? What's the drawback to having more? In sort of an apples-to-apples world, more may be helpful. I think in the particular competitor in question, it's quite a large device. You know, I think when we look at all of the choices that one weighs, when they're making a choice about the technology they adapt, they adopt, size on body is a really important consideration. So when we look at what does Omnipod 5 offer? Plenty of insulin capacity, great clinical outcomes, reliable, affordable through the pharmacy channel. We've got the right product to go win in type two. Okay, that's helpful. So let's transition to international, which was obviously one of the standouts, if not the standout, right, on the Q2 call, or the Q2 reported results. I guess the question is, you know, given these new market launches and the business model, you know, why can't you continue this momentum in the second half and maybe even beyond? Yeah. No, I'll start with that. As you know, everywhere Omnipod 5 goes, it's been a winner. And we have increased our guidance for international 500 basis points at the end of 1Q for the full year, and another 600 basis points. So 1,100 basis points so far for 2024. So that tells you even exceeded our expectations that were of significant growth, so we're very excited by that. Second thing is, we're moving as fast as we can. As you know, we're in the U.K., Germany, France, and we talked about more countries in the coming months here. So we're going to continue to play that same play that we know how to do, and we anticipate that continued growth in international to carry us into 2025 and beyond. Are there any major markets that you're not in yet with Omnipod 5? There are a few, so maybe just a couple quick fill-ins. So we announced we entered France in June, but we're very early in that launch, so that's kind of the next big market that will get the benefit of Omnipod 5. We also shared on our on our Q2 call, we'll be bringing Omnipod 5 to Canada, Australia, Switzerland, Belgium, Nordics, and Italy, and we're kind of deep into launch planning for all those. Canada is a pretty big market for us, and the Nordics are very good markets. But you didn't give any timing. France, so did France contribute much in Q2? So is that... I'm trying to just understand, the big market, is that more of a second half 2024 contribution? We just announced that we entered France right at the end of the second quarter. So we entered the market in the second quarter, again, with our referring- So my- France has more ahead of us. Yeah. Much more ahead. And these other markets that you mentioned, Eric, did you give a timing? Is that 2024, 2025? No, no timeline. All in 2025. Haven't yet given specifics- All in 2025. Yeah. The Nordics, Canada, Italy. Yeah. ... Okay. Actually, one quick update on that. We'll also, because we've built Omnipod 5 as a platform, now that we have the benefits of sensor integrations, we'll also be bringing G7, for example, to international markets in 2025 as well. The work to do that is mostly about supply chain, regulatory, and local market access, so we'll just do it market by market as it's time to do the local market work. I want to do a quick build on international that I think it's important around pricing. One of the interesting things we're seeing as we're going into these international markets is the value of the customer experience and outcomes that Omnipod 5 brings is being valued as we negotiate price. So what we're seeing as we're launching in the international markets, that reward in the pricing is coming through. So we expect that to also be a tailwind, as we have been doing in the current launches and as we move into 2025. You're getting a price premium? Correct. Have you quantified that? Again, every market is different. Every market goes through slightly different adoption, so we haven't been specific, but you're seeing that appreciation of the value that it brings being rewarded. And just a reminder, Larry, we've been investing in evidence as part of that strategy for a number of years. So we did a randomized controlled trial against open loop pumps. The folks on an open loop pump versus those on Omnipod 5 and also against MDI. We've done that. We've done evidence with each of our sensor partners. The body of evidence that we're building for Omnipod 5, which all sits on top of our very strong real-world evidence, is a big part of helping ensure that we get appropriate value for Omnipod 5. You talked about G7 integration next year. You have Libre 2 integration, 2 Plus integration in I think U.K. and Netherlands. What's the plan for Libre 2 Plus integration outside the U.S. with Omnipod 5? So just like we just said on G7, bringing additional sensor integrations is kind of a market-by-market decision. It's really supply chain, regulatory, and then, local market access, and so we'll be bringing additional sensors to global markets, market by market. You talked about the evidence generation, Eric. Are there any of these major... I don't have a list in front of me. You've got a few studies ongoing. Any major ones like where you expect data, you know, second half of this year, early next year? The couple studies that we announced at ADA that we're really excited about, Larry, but they're just at the beginning phases. We're doing the next of our evolution series of trials. That's the fully closed-loop research that we're doing. Sure. We did the first of those studies in New Zealand late 2023, presented that data at ATTD in the first quarter of this year. We'll be doing the next phase of that fully closed-loop research. We also announced that we'll be starting what we're calling our STRIVE study, and that's a study with building on some learnings from the work we're doing on fully closed loop. We see an opportunity to do more of an iteration on the Omnipod 5 AID experience, and that'll be testing a lower set point and some other user experience benefits. So we've got a continued clinical development pipeline coming as well. That's helpful. Ana, we touched upon this a little bit earlier, 2025. I mean, to us, it looks like, you know, it should be a strong year for Insulet. Full impact of type two, Libre integration in the U.S., you talked about, and that's Libre 2 Plus, right? Correct. Correct. And then continued momentum outside the U.S. What are some of the puts and takes we should consider for next year, and is there any reason growth would decelerate next year? Just as an aside, you know, you do have kind of a net stocking negative impact in 2024. That creates a little bit of an easier comp next year. Yeah. So again, we're not providing guidance here for 2025, but you've hit on a lot of the moving parts that make all of us at Insulet feel very proud of the investments we've been making coming to fruition. So we feel we have really good momentum, and I mean, you've mentioned them. I think it's what our CEO sometimes says: "There's so many that you can't keep them in your short-term memory," because I mean, there's G6 iOS, there's you know, just G7, G6 iOS. There's a lot going on with T2 in the US. So as I said before, we want to really wrap up 2024, see more evidence of how we're paving the way here in T2, and we'll come back with more specifics in 2024. But you're absolutely right. I mean, we see a lot of good tailwinds, and these are not coincidences. These These are all the investments we've been, as a team, working towards and preparing, so more to come. That's helpful. We touched on margins already. You're committed to a hundred plus, insulin- Yes, I actually. Let me give some additional color on margin. So when you look at gross margin, we said we're going to be, in 2024, at the high end of our guidance of 69%. That is inclusive of our decision around Omnipod Go, which is a fantastic decision to just use one platform, Omnipod 5, for basal and for all of the insulin needs. So, we will have better product lifecycle management. The reason I wanted to mention the gross margin is a lot of the gross margin expansion we've experienced over the last few years have come from pricing in the U.S. as we penetrated into the pharmacy channel. Now we're very high nineties penetration in pharmacy. We continue to expect to hold that, but the go-forward margin expansion is going to come from our scale. So that's, as I said, type two is going to provide even more of that scale, type one, international growth. The other thing is really hardcore manufacturing. We do the Kaizens, and all of those things. So, and in addition, you might have seen our launch in, of the Malaysia plant. Malaysia is going to be a super competitive plant in our mix of manufacturing capabilities and also in the competitive nature of the production that they'll be doing. So again, we feel very confident at the gross margin, and then when you take it down to the operating margin level, because of that volume growth we're seeing, our revenue expectation will continue to grow. It just provides more of that fixed cost leverage, so. Historically, I think you had a goal of 70% gross margin. Is that right? Correct. You're almost there. You know, you kind of hit there, I think, in Q2 on an underlying basis, right? Yes. What is it, so the ceiling is obviously higher. You know, I guess the question is, how much higher? What kind of headroom do you see for the gross margin? So we'll come back and provide more color in 2025, but what I was trying to describe here is that the effort to bring that margin expansion, which we're highly committed to, is going to be more from volume and from hardcore manufacturing improvements, and less from that pricing benefit that we saw, especially with the U.S. pharmacy channel. So there will be pricing. There will be margin expansion. It's just going to come at a slightly different pace than the windfall we've seen over the last few years. Malaysia should be helpful as well. Absolutely helpful. The seventy is not the ceiling, that's the message? Correct. But the rate of growth is not what you shouldn't model this, looking at the prior rate of growth. The rate of growth will continue to grow, but at a slower pace. Got it. And, Ana, is there any thought, any updated thoughts on an investor day, or, you know, any kind of, you know, outlook, LRP or, you know, just more, you know, long-term view? Have you, you know, where do you stand on that? No, it's a very timely question. We're still working through it. Stay tuned. We're trying to define whether we do it in the next few months or early in the new year. So we're just still working out the details and the timing, but stay tuned. We definitely owe it to all of you guys, and we want to be out there providing more of a long-term plan for everyone. Eric, just jumping around, I guess I'll ask on the GLP-1 question. I didn't ask about it during the type two conversation, but that's where I think it's most relevant. You know, you probably saw the stock reaction when Lilly provided the top-line data on the, I think the 94% headline, prediabetes, you know, prevention to diabetes progression. Yeah, I guess, what's your view and why doesn't this why isn't this a headwind for the type two opportunity? A couple of perspectives on that one, Larry. First place to start, there are two and a half million people who live with insulin-intensive Type 2 diabetes today in the U.S. That market's under 5% penetrated. There are a lot of people who need our help, and those are the first people we're going to go drive impact with our Omnipod 5 Type 2 indication. Secondly, you know, when we step back, that data is consistent with data that's been previously shown on the Mounjaro side. And what we know from the research that we've published on our investor website about GLP-1 is about 55% of people stop using the GLP-1 after one year. To get the benefits shown in Surmount, folks have to be on those drugs forever. So if we step back, what does that mean in order to reduce the number of people who require insulin in the U.S.? It means a very large portion of the 30 million people with diabetes would have to stay on GLP-1s in perpetuity. There's no evidence that that's possible. The economic reasons and the tolerability challenges, which show up in the data and explain why 50%-55% of people stop taking them after a year, just we don't see it. And so we don't actually see an impact on the number of folks who require insulin over time. Okay. And Libre 3, I know you're going to Libre 2 Plus in the U.S. What is the process to get to Libre 3 beyond that? We're starting with Libre 2 Plus. It's a terrific sensor. It's on the market now in the U.K. and Netherlands, and helping us drive impact there. We haven't yet shared timing for Libre 3, Larry. We're getting better and better at sensor integrations as we go, and we're excited to share that update. We're almost out of time. I want to give you guys the last word. You guys, I'll throw it out to either of you, but maybe Ana, since you've been here now for about six months, you know- Actually, four months. Four months. What are you most excited about? Yes. So I'll start by saying, you know, I joined Insulet because it's a 20%+ company, revenue growth for eight years and a trajectory for that to continue, and I validated that. It's a great team with a great culture, with a ton of innovation. And if there's one thing that has surprised me, as I've looked under the coverage of our research and development and innovation, our problem is that we have a lot of ideas and a lot of prioritization to be made. And that's why I think it's sometimes hard for us to answer precisely, when things will launch. But that's a really good problem because we're ahead of the market, and we're just going to stay even further ahead as we continue to make really good decisions. The last thing I'll say is, as a company, we're sustained. We are free cash flow positive and growing, so we are in a very, very unique position, financially, to support all the people with diabetes and to support our shareholders with investor returns. Great. Great place to end. Thank you for being here. Thank you. Thank you, Larry.